Literature DB >> 15940265

Enhanced radiation damage of tumor vasculature by mTOR inhibitors.

Eric T Shinohara1, Carolyn Cao, Ken Niermann, Yi Mu, Fenghua Zeng, Dennis E Hallahan, Bo Lu.   

Abstract

It is known that radiation activates the phosphoinositol-3 kinase (PI3K)/Akt pathway and that inhibition of PI3K or Akt sensitizes tumor vasculature to radiotherapy. Mammalian target of rapamycin (mTOR) is a downstream target of Akt, and we hypothesized that irradiation activates mTOR signaling in both glioma and endothelial cells (ECs) and that radiosensitization results from inhibiting mTOR signaling. mTOR inhibitors, rapamycin and RAD001 (everolimus) were found to radiosensitize vascular ECs, but failed to sensitize glioma cells as determined by clonogenic assay. Therefore, we investigated the anti-angiogenic effects of mTOR inhibitors. Increased phospho-mTOR protein was detected in irradiated human umbilical vein endothelial cells (HUVEC), but not in GL261 glioma cells. Phospho-S6, a biomarker for mTOR signaling, was also found to be induced following irradiation in HUVEC and this effect was inhibited by PI3K or mTOR inhibitors. Significant increase in cleaved caspase 3 was detected when Rad001 was combined with radiation. Endothelial tube formation was significantly diminished following treatment with rapamycin and 3 Gy of radiation. Histological sections of GL261 tumors from mice showed a greatly reduced vascular density when treated with RAD001 and radiation. Power Weighted Doppler of glioma xenografts in mice showed a significant reduction in vasculature and blood flow compared with mice treated with 3 Gy or RAD001 alone. We conclude that irradiation activates mTOR signaling in vascular endothelium and that rapamycin and RAD001 increased apoptosis of ECs in response to radiation. To the authors' best knowledge this is the first study which demonstrates that mTOR inhibitors may be a way to target the vasculature by radiosensitizing the vascular endothelium resulting in better tumor control as seen in experiments demonstrating increased tumor growth delay in mice treated with rapamycin with radiation compared with mice treat with either treatment alone. We conclude that mTOR inhibitors have increased efficacy as antiangiogenics when combined with radiation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15940265     DOI: 10.1038/sj.onc.1208715

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  63 in total

1.  Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks.

Authors:  Jann N Sarkaria; Eva Galanis; Wenting Wu; Allan B Dietz; Timothy J Kaufmann; Michael P Gustafson; Paul D Brown; Joon H Uhm; Ravi D Rao; Laurence Doyle; Caterina Giannini; Kurt A Jaeckle; Jan C Buckner
Journal:  Clin Cancer Res       Date:  2010-10-04       Impact factor: 12.531

2.  Regulation of protein synthesis by ionizing radiation.

Authors:  Steve Braunstein; Michelle L Badura; Qiaoran Xi; Silvia C Formenti; Robert J Schneider
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

3.  The mTOR inhibitor rapamycin suppresses DNA double-strand break repair.

Authors:  Honghong Chen; Zhefu Ma; Robert P Vanderwaal; Zhihui Feng; Ignacio Gonzalez-Suarez; Shenming Wang; Jiuqin Zhang; Joseph L Roti Roti; Susana Gonzalo; Junran Zhang
Journal:  Radiat Res       Date:  2010-10-26       Impact factor: 2.841

4.  Improved antitumor effect of ionizing radiation in combination with rapamycin for treating nasopharyngeal carcinoma.

Authors:  Di Wang; Lichen Gao; Xueting Liu; Chuang Yuan; Guihua Wang
Journal:  Oncol Lett       Date:  2017-05-19       Impact factor: 2.967

5.  Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.

Authors:  Y-P Jin; N M Valenzuela; M E Ziegler; E Rozengurt; E F Reed
Journal:  Am J Transplant       Date:  2014-03-01       Impact factor: 8.086

6.  Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.

Authors:  Luise Maute; Viktor Grünwald; Steffen Weikert; Ulrich Kube; Thomas Gauler; Christoph Kahl; Iris Burkholder; Lothar Bergmann
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-21       Impact factor: 4.553

7.  Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.

Authors:  Kwang Woon Kim; Luigi Moretti; Lauren Rhea Mitchell; Dae Kwang Jung; Bo Lu
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

8.  Targeted therapy in the treatment of malignant gliomas.

Authors:  Rimas V Lukas; Adrienne Boire; M Kelly Nicholas
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

9.  Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma.

Authors:  Oleksandr Ekshyyan; Youhua Rong; Xiaohua Rong; Kavita M Pattani; Fleurette Abreo; Gloria Caldito; John Kai Siung Chang; Federico Ampil; Jonathan Glass; Cherie-Ann O Nathan
Journal:  Mol Cancer Ther       Date:  2009-07-22       Impact factor: 6.261

Review 10.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

Authors:  Jaclyn LoPiccolo; Gideon M Blumenthal; Wendy B Bernstein; Phillip A Dennis
Journal:  Drug Resist Updat       Date:  2007-12-31       Impact factor: 18.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.